Received: FebruAccepted: JPublished: August 12, 2021Ĭopyright: © 2021 Brümmer et al. PLoS Med 18(8):Īcademic Editor: Amitabh Bipin Suthar, PLOS Medicine Editorial Board, UNITED STATES (2021) Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. Our analysis was limited by the included studies’ heterogeneity in design and reporting.Ĭitation: Brümmer LE, Katzenschlager S, Gaeddert M, Erdmann C, Schmitz S, Bota M, et al.
Concerns of bias were raised across all datasets, and financial support from the manufacturer was reported in 24.1% of datasets. The best Ag-RDT sensitivity was found with anterior nasal sampling (75.5%, 95% CI 70.4% to 79.9%), in comparison to other sample types (e.g., nasopharyngeal, 71.6%, 95% CI 68.1% to 74.9%), although CIs were overlapping. Testing in the first week from symptom onset resulted in substantially higher sensitivity (83.8%, 95% CI 76.3% to 89.2%) compared to testing after 1 week (61.5%, 95% CI 52.2% to 70.0%). Of instrument-free Ag-RDTs, Standard Q nasal performed best, with 80.2% sensitivity (95% CI 70.3% to 87.4%). LumiraDx showed the highest sensitivity, with 88.2% (95% CI 59.0% to 97.5%). Sensitivity increased to 76.3% (95% CI 73.1% to 79.2%) if analysis was restricted to studies that followed the Ag-RDT manufacturers’ instructions. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity and specificity were 71.2% (95% CI 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy datasets with 112,323 samples. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS-2 assessment tool.
Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcription polymerase chain reaction (RT-PCR) testing. We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until 30 April 2021.
BRIDGE DIAGNOSTICS COVID FREE
Second, create a novel, funded partnership with pharmacy chains that will enable them to continue offering free COVID-19 vaccinations and treatments to the uninsured through their network or retail locations as has been done during the COVID-19 Public Health Emergency (PHE).We registered the review on PROSPERO (registration number: CRD42020225140).First, provide support for the existing public sector vaccine safety net, which is implemented through local health departments (LHDs) and Health Resources and Services Administration (HRSA) supported health centers.‘HHS Bridge Access Program For COVID-19 Vaccines and Treatments’: The program will create a $1.1 billion public-private partnership to help maintain uninsured individuals’ access to COVID-19 care at their local pharmacies, through existing public health infrastructure, and at their local health centers. Department of Health and Human Services (HHS) announced the ‘HHS Bridge Access Program For COVID-19 Vaccines and Treatments Program’(“Program”) to maintain broad access to COVID-19 vaccines for millions of uninsured Americans.
0 kommentar(er)
